Recognizing a Visionary Leader in Advancing Healthcare Access for Minority and Vulnerable Populations Worldwide ATLANTA, GA - ...

Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum ATLANTA, GA - February 5, 2025 (NEWMEDIAWIRE ...

This versatility allows GeoVax to develop vaccines targeting multiple aspects of a single pathogen or several pathogens simultaneously. Originally developed as a safer smallpox vaccine ...

GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing vaccines with a current market capitalization of $19.78 million, announced today that its shareholders have ...

ATLANTA, GA - February 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have been given an average rating of “Buy” by the seven analysts that are currently covering the firm, Marketbeat reports.

Dr. Montgomery Rice will be formally recognized at the Atlanta Business Chronicle's second annual Health Care Champion Awards ceremony on March 20, 2025.

Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in vaccines and immunotherapies, has shared updates about its development-stage advanced Modified Vaccinia Ankara ...

ATLANTA, GA - February 5, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious ...